Skip to main content
Aurélie Barrail-Tran on Muck Rack

Aurélie Barrail-Tran

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Aurélie

Contact Aurélie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir - Communications Medicine

|
By Gilbert Mchantaf, Adeline Mélard, Elise Gardiennet, Frédéric Lemoine, Aurélie Barrail-Tran, Laurence Meyer, Sylvie Orr
| Nature Verified
Abstract Relatively few studies have investigated HIV-1 persistence in tissues, especially in healthy people-living-with-HIV-1 (PLWH) on a successful antiretroviral regimen containing second generation integrase inhibitors. In the ANRS EP64 DOLUVOIR, we explore HIV-1 persistence in five accessible anatomical sites in 20 PLWH on an efficient first-line ART regimen containing dolutegravir with virological load <50 copies/mL: PBMCs, rectum, adipose tissue, lymph node and sperm.
Open in Who Shared Issue with article?

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells - Nature Communications

|
By Caroline Passaes, Delphine Desjardins, Valérie Monceaux, Federico Perdomo-Celis, Cyril Planchais, Nathalie Dereuddre-Bosquet, Jeremie Guedj, Michaela Müller-Trutwin, Hugo Mouquet, Véronique Avettand-Fenoel, Roger Le Grand, Adeline Mélard, Maël Gourvès, Nastasia Dimant, Aurélie Barrail-Tran, Francis Relouzat
| Nature Verified
Abstract HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs.
Open in Who Shared Issue with article?
See all 2 articles